Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Pandya

Showing results (171-180 of 188) with videos related to

Pageof 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2020
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced ChondrosarcomaWilliam D Tap, Victor M Villalobos, Gregory M Cote, et al.
Cancer|September 21, 2016
A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neckAntonio Jimeno, Marshall R Posner, Lori J Wirth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2010
Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumorsJennifer R Diamond, Bruno R Bastos, Ryan J Hansen, et al.
Vaccines|February 26, 2022
Metrics from Wearable Devices as Candidate Predictors of Antibody Response Following Vaccination against COVID-19: Data from the Second TemPredict StudyAshley E Mason, Patrick Kasl, Wendy Hartogensis, et al.
Global Advances in Integrative Medicine and Health|October 28, 2025
A Randomized Trial Testing a Novel Mind and Body Intervention for Depression: Cognitive Behavioral Therapy (CBT) and Whole-Body Hyperthermia (WBH)Ashley E Mason, Wendy Hartogensis, Anoushka Chowdhary, et al.
Arxiv|December 19, 2025
Monitoring Deployed AI Systems in Health CareTimothy Keyes, Alison Callahan, Abby S Pandya, et al.
The Review of Scientific Instruments|November 29, 2014
Characteristics of the positive ion source at reduced gas feedS K Sharma, P Bharathi, V Prahlad, et al.
Nature Medicine|February 24, 2023
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trialIngo K Mellinghoff, Min Lu, Patrick Y Wen, et al.
Nature Medicine|July 3, 2023
Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trialIngo K Mellinghoff, Min Lu, Patrick Y Wen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2020
Ivosidenib in Isocitrate Dehydrogenase 1<i>-</i>Mutated Advanced GliomaIngo K Mellinghoff, Benjamin M Ellingson, Mehdi Touat, et al.
Pageof 19

Showing results (171-180 of 188) with videos related to

Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2020
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced ChondrosarcomaWilliam D Tap, Victor M Villalobos, Gregory M Cote, et al.
Cancer|September 21, 2016
A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neckAntonio Jimeno, Marshall R Posner, Lori J Wirth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2010
Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumorsJennifer R Diamond, Bruno R Bastos, Ryan J Hansen, et al.
Vaccines|February 26, 2022
Metrics from Wearable Devices as Candidate Predictors of Antibody Response Following Vaccination against COVID-19: Data from the Second TemPredict StudyAshley E Mason, Patrick Kasl, Wendy Hartogensis, et al.
Global Advances in Integrative Medicine and Health|October 28, 2025
A Randomized Trial Testing a Novel Mind and Body Intervention for Depression: Cognitive Behavioral Therapy (CBT) and Whole-Body Hyperthermia (WBH)Ashley E Mason, Wendy Hartogensis, Anoushka Chowdhary, et al.
Arxiv|December 19, 2025
Monitoring Deployed AI Systems in Health CareTimothy Keyes, Alison Callahan, Abby S Pandya, et al.
The Review of Scientific Instruments|November 29, 2014
Characteristics of the positive ion source at reduced gas feedS K Sharma, P Bharathi, V Prahlad, et al.
Nature Medicine|February 24, 2023
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trialIngo K Mellinghoff, Min Lu, Patrick Y Wen, et al.
Nature Medicine|July 3, 2023
Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trialIngo K Mellinghoff, Min Lu, Patrick Y Wen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2020
Ivosidenib in Isocitrate Dehydrogenase 1<i>-</i>Mutated Advanced GliomaIngo K Mellinghoff, Benjamin M Ellingson, Mehdi Touat, et al.
Pageof 19